JCR Pharmaceuticals Co., Ltd. (4552) AI Stock Analysis

• Market Cap: ¥84.77B
• Dividend Yield: 2.92%
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: -22.86%
• EPS Growth: -188.19%
• Country: JP
• Employees: 934
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): -33.80
• Shares Outstanding: 129,686,310
• 10 Day Avg. Volume: 2,415,850
• 30 Day Avg. Volume: 1,676,473
• PEG Ratio: <0.01
• Price to Book (P/B): 1.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥576.67
• Price Target Upside: -15.81% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: ¥707.00 ▲(3.21%Upside)

The overall stock score for JCR Pharmaceuticals Co., Ltd. reflects significant financial challenges, including declining profitability and increasing debt levels. Despite this, the stock shows strong bullish momentum in technical analysis, which partially offsets the financial concerns. The negative P/E ratio highlights the current unprofitability, but the dividend yield provides some support to the valuation.

JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company Description

JCR Pharmaceuticals Co., Ltd. (4552) is a Japanese pharmaceutical company specializing in biopharmaceuticals and regenerative medicine. The company is involved in the development, manufacturing, and marketing of pharmaceuticals with a focus on rare diseases, enzyme replacement therapies, and regenerative treatments. JCR Pharmaceuticals is known for its innovative approaches in the biotechnology sector, leveraging its expertise in cell and gene therapies to address unmet medical needs globally.

How the Company Makes Money

JCR Pharmaceuticals makes money primarily through the development and sale of its proprietary pharmaceutical products. The company's key revenue streams include the commercialization of enzyme replacement therapies for rare diseases and regenerative medicine products. JCR collaborates with global pharmaceutical companies and research institutions to expand its product offerings and access new markets. Additionally, the company licenses its technologies and intellectual properties to other entities, generating royalty income. Strategic partnerships and joint ventures also play a significant role in enhancing JCR's research capabilities and market reach, contributing to its financial growth.

JCR Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary

JCR Pharmaceuticals Co., Ltd. faces significant financial challenges. The income statement shows declining profitability and revenue, with negative margins indicating operational inefficiencies. The balance sheet is stable but under pressure from increasing debt levels. Cash flow issues are apparent with negative operating and free cash flows, indicating liquidity constraints. Overall, the company needs to address revenue growth, cost management, and debt levels to improve its financial health.

Income Statement

The income statement reflects significant volatility. Gross profit margins were generally strong in past years but have suffered recently due to declining revenue and increased costs. The net profit margin has turned negative in the latest year, indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in the most recent year. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a stable equity base, but with a concerning rise in total debt, increasing the debt-to-equity ratio. Return on equity has turned negative due to recent net losses. However, the equity ratio remains healthy, indicating a strong asset base relative to liabilities. The financial structure suggests potential risks if the current trend of increasing debt continues.

Cash Flow

The cash flow statement highlights challenges with a negative free cash flow and operating cash flow in the latest period. The operating cash flow to net income ratio shows poor cash generation from operations, suggesting inefficiencies. The free cash flow has decreased significantly, raising concerns about the company's ability to fund operations and growth without external financing.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	33.07B	42.87B	34.34B	51.08B	30.09B
Gross Profit	21.55B	31.25B	25.46B	40.62B	22.27B
EBITDA	-2.88B	10.53B	6.97B	21.88B	10.18B
Net Income	-4.76B	5.51B	3.77B	14.51B	6.89B
Balance Sheet
Total Assets	104.86B	102.23B	94.94B	97.13B	73.78B
Cash, Cash Equivalents and Short-Term Investments	13.20B	18.76B	13.28B	30.98B	26.26B
Total Debt	38.10B	23.30B	22.80B	18.10B	18.10B
Total Liabilities	57.42B	45.75B	42.52B	46.05B	35.23B
Stockholders Equity	47.04B	56.18B	52.16B	50.88B	38.38B
Cash Flow
Free Cash Flow	-15.37B	7.22B	-14.06B	-2.04B	2.81B
Operating Cash Flow	-5.49B	9.31B	-5.50B	9.29B	10.34B
Investing Cash Flow	-9.87B	-2.69B	-15.00B	-3.25B	-3.29B
Financing Cash Flow	9.74B	-2.03B	1.95B	-2.18B	8.30B

JCR Pharmaceuticals Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 685.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Positive. The current price of 685 is above the 20-day moving average (MA) of 603.20, above the 50-day MA of 556.98, and above the 200-day MA of 563.19, indicating a bullish trend. The MACD of 42.55 indicates Negative momentum. The RSI at 75.65 is Negative, neither overbought nor oversold. The STOCH value of 88.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4552.

JCR Pharmaceuticals Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4569	77 Outperform	¥80.22B	9.64		1.64%	8.83%	70.61%
4886	76 Outperform	¥66.69B	13.93		2.00%	2.06%	-32.48%
4534	67 Neutral	€103.96B	19.05	4.35%	2.62%	5.31%	90.37%
Sector *	65 Neutral	¥355.15B	11.37	-2.99%	2.48%	11.78%	-10.17%
3341	62 Neutral	$104.50B	77.47	2.35%	0.69%	5.94%	-45.43%
4552	56 Neutral	¥84.77B	―		2.92%	-22.86%	-188.19%
4565	43 Neutral	¥79.27B	―	-3.36%	―	87.83%	75.84%

JCR Pharmaceuticals Co., Ltd. Corporate Events

JCR Pharmaceuticals Completes Treasury Stock Disposition for Compensation

JCR Pharmaceuticals Co., Ltd. announced the completion of payment procedures for the disposition of treasury stock as restricted stock compensation. This move, involving 111,000 shares of common stock at 518 yen per share, is part of a strategic initiative to align the interests of directors, executive officers, and employees with the company’s long-term goals, potentially enhancing its operational effectiveness and market position.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Treasury Stock Disposition for Incentive Plan

JCR Pharmaceuticals Co., Ltd. announced a plan to dispose of 111,000 shares of its treasury stock as part of a restricted stock compensation plan aimed at incentivizing its directors and employees. This initiative is designed to align the interests of the company’s leadership with those of its shareholders, promoting sustained corporate value enhancement and ensuring continued commitment from key personnel.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Strengthens Ties with MEDIPAL HOLDINGS for Global Expansion

JCR Pharmaceuticals Co., Ltd. has announced its relationship with MEDIPAL HOLDINGS CORPORATION, which is its largest shareholder with a 23.86% voting rights ownership. The companies have a business alliance to enhance corporate value and growth, leveraging MEDIPAL’s distribution strengths and JCR’s pharmaceutical R&D capabilities. Recent agreements between the two include exclusive negotiation rights for the global commercialization of JCR’s new drug candidates targeting ultra-rare lysosomal storage diseases, and licensing agreements for treatments like JR-471 and JR-446. These collaborations are expected to bolster JCR’s industry positioning and operational capabilities.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Gain on Deferred Income Taxes

JCR Pharmaceuticals Co., Ltd. has announced a recognition of gain on deferred income taxes for the fiscal year ended March 31, 2025, resulting in a corporate tax adjustment profit of 1,771 million yen. This adjustment reflects the company’s performance trends and careful review of deferred tax assets’ recoverability, impacting the consolidated financial results positively and demonstrating JCR’s strategic financial management.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Leadership Transition for 2026

JCR Pharmaceuticals has announced a leadership transition effective April 1, 2026, marking a generational shift as the company celebrates its 50th anniversary. Toru Ashida will become Chairman and Hiroyuki Sonoda will assume the role of President, while current Chairman, President, and CEO Shin Ashida will transition to Founder and Director. This change aims to strengthen the management structure and enhance long-term corporate value.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Reports Significant Financial Losses for FY2024

JCR Pharmaceuticals reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 22.9% and a net loss of 4,759 million yen. The company is undergoing changes, including the exclusion of Mycenax Biotech Inc. from its subsidiaries and adjustments in accounting policies, as it aims to improve its financial standing and operational efficiency in the coming fiscal year.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Consistent Dividend Distribution for 2025

JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.